HLA-B27 and the pathogenesis of spondyloarthritis

Tissue Antigens

Volumn 60, Issue 3, 2002, Pages 191-205

  Ramos, M ^a   Lopez De Castro J A ^b  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Ankylosing spondylitis; HLA B27; Human; MHC; Spondyloarthropathy

Indexed keywords

HLA ANTIGEN CLASS 1; HLA B27 ANTIGEN;

ANKYLOSING SPONDYLITIS; ANTIGEN RECOGNITION; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR BIOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN MOTIF; REVIEW; SPONDYLOARTHROPATHY; GENETICS; SPONDYLARTHRITIS;

HLA-B27 ANTIGEN; HUMANS; POLYMORPHISM, GENETIC; SPONDYLARTHRITIS;

EID: 18744386087     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.2002.600301.x     Document Type: Review

References (81)

1. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet 1973: 1: 904-7.
2. Brewerton DA, Caffrey M, Nicholls A, Walters D, Oates JK, James DC. Reiter's disease and HL-A 27. Lancet 1973: 2: 996-8.
3. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2m. An animal model of HLA-B27-associated human disorders. Cell 1990: 63: 1099-112.
4. Benjamin R, Parham P. Guilt by association: HLA?x?B27 and ankylosing spondylitis. Immunol Today 1990: 11: 137-42.
5. Allen RL, Bowness P, McMichael A. The role of HLA-B27 in spondyloarthritis. Immunogenetics 1999: 50: 220-7.
6. Edwards JC, Bowness P, Archer JR. Jekyll and Hyde: The transformation of HLA-B27. Immunol Today 2000: 21: 256-60.
7. Mear JP, Schreiber KL, Münz C et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol 1999: 163: 6665-70.
8. Colbert RA. HLA-B27 misfolding: A solution to the spondyloarthropathy conundrum? Mol Med Today 2000: 6: 224-30.
9. Gonzalez-Roces S, Alvarez MV, Gonzalez S et al. HLA-B27 polymorphism and worl-wide susceptibility to ankylosing spondylitis. Tissue Antigens 1997: 49: 116-23.
10. Armas JB, Gonzalez S, Martinez-Borra J et al. Susceptibility to ankylosing spondylitis is independent of the Bw4 and Bw6 epitopes of HLA-B27 alleles. Tissue Antigens 1999: 53: 237-43.
11. Sudarsono D, Hadi S, Mardjuadi A et al. Evidence that HLA-B*2706 is not protective against spondyloarthropathy. J Rheumatol 1999: 26: 1534-6.
12. Brown M, Jepson A, Young A, Whittle H, Greenwood B, Wordsworth P. Spondyloarthritis in West Africa: Evidence for a non-B27 protective effect. Ann Rheum Dis 1997: 56: 68-70.
13. Lopez-Larrea C, Sujirachato K, Mehra NK et al. HLA-B27 subtypes in Asian patients with ankylosing spondylitis. Evidence for new associations. Tissue Antigens 1995: 45: 169-76.
14. García-Fernández S, Gonzalez S, Miña Blanco A et al. New insights regarding HLAB27 diversity in the Asian population. Tissue Antigens 2001: 58: 259-62.
15. Mongkolsuk T, Tardtong P. Raksa S, Jun-pong S, Sujirachato K, Mulpruek P. Association between HLA-B27 alleles and spondyl-oarthropathies in Thailand. Tissue Antigens 2002: 59: 70.
16. Ren EC, Koh WH, Sim D, Boey ML, Wee GB, Chan SH. Possible protective role of HLA-B*2706 for ankylosing spondylitis. Tissue Antigens 1997: 49: 67-9.
17. Nasution AR, Mardjuadi A, Kunmartini S et al. HLA-B27 subtypes positively and negatively associated with spondyloarthropathy. J Rheumatol 1997: 24: 1111-4.
18. D'Amato M, Fiorillo MT, Carcassi C et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 1995: 25: 3199-201.
19. Olivieri I, Padula A, Cianco G et al. The HLA-B*2709 subtype in a patient with undifferentiated spondarthritis. Ann Rheum Dis 2000: 59: 654-5.
20. Olivieri I, Ciancio G, Padula A et al. The HLA-B*2709 subtype confers susceptibility to spondylarthropathy. Arthritis Rheum 2002: 46: 553-4.
21. Marchionni L, Modena V, Roggero R, Curtoni ES. The polymorphism of HLA-B27 and the seronegative spondyloarthropathies in the Italian population. Presented at the 13th European Histocompatibility Conference, Crete 1999 European Federation for Immunogenetics, 1999.
22. Mathieu A, Sorrentino R. HLA-B*2709 and spondyloarthropathy: Comments on the paper by Olivieri et al. Arthritis Rheum, in press.
23. Yamaguchi A, Tsuchiya N, Mitsui H et al. Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a role of the peptide-anchoring B pocket. Arthritis Rheum 1995: 38: 1672-7.
24. Khan MA, Kushner I, Braun WE. B27-negative HLA-BW16 in ankylosing spondylitis. Lancet 1978: 1: 1370-1.
25. Crivellato E, Zacchi T. HLA-B39 and the axial type of psoriatic arthritis. Acta Derm Venereol 1987: 67: 249-50.
26. Sobao Y, Tsuchiya N, Takiguchi M, Tokunaga K. Overlapping peptide-binding specificities of HLA-B27 and B39. Evidence for a role of peptide supermotif in the pathogenesis of spondylarthropathies. Arthritis Rheum 1999: 42: 175-81.
27. Lopez-Larrea C, Mijiyawa M, Gonzalez S et al. Ankylosing spondylitis is associated with HLA-B*1403 in a West African population. Arthritis Rheum, in press.
28. Ellis JM, Mack SJ, Leke RF, 0uakyi I, Johnson AH, Hurley CK. Diversity is demonstrated in class I HLA-A and HLA-B alleles in Cameroon, Africa: Description of HLA-A*03012, *2612, *3006 and HLA-B*1403, *4016, *4703. Tissue Antigens 2000: 56: 291-302.
29. DiBrino M, Parker KC, Margulies DH et al. The HLA-B14 peptide binding site can accommodate peptides with different combinations of anchor residues. J Biol Chem 1994: 269: 32426-34.
30. Hermann E, Yu DT, Meyer zum Buschenfelde KH, Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 1993: 342: 646-50.
31. Ugrinovic S, Mertz A, Wu P, Braun J, Sieper J. A single nonamer from the Yersinia 60Kd heat shock protein is the target of HLA-B27 restricted CTL response in Yersinia-induced reactive arthritis. J Immunol 1997: 159: 5715-23.
32. Fiorillo MT, Maragno M, Butler R, Dupuis ML, Sorrentino R. CD8 (+) T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with ankylosing spondylitis. J Clin Invest 2000: 106: 47-53.
33. Zhou M, Sayad A, Simmons WA et al. The specificity of peptides bound to human histocompatibility leukocyte antigen (HLA) -B27 influences the prevalence of arthritis in HLA-B27 transgenic rats. J Exp Med 1998: 188: 877-86.
34. Garcia F, Galocha B, Villadangos JA et al. HLA-B27 (B*2701) specificity for peptides lacking Arg2 is determined by polymorphism outside the B pocket. Tissue Antigens 1997: 49: 580-7.
35. Boisgérault F, Tieng V, Stolzenberg MC et al. Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants: Implications for susceptibility to spondylarthropathies. J Clin Invest 1996: 98: 2764-70.
36. Garcia F, Rognan D, Lamas JR, Marina A, Lopez de Castro JA. An HLA-B27 polymorphism (B*2710) that is critical for T-cell recognition has limited effects on peptide specificity. Tissue Antigens 1998: 58: 1-9.
37. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. Identification of self peptides bound to purified HLA-B27. Nature 1991: 353: 326-9.
38. Rotzschke O, Falk K, Stevanovic S, Gnau V, Jung G, Rammensee HG. Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs. Immunogenetics 1994: 39: 74-7.
39. Garcia F, Marina A, Lopez de Castro JA. Lack of carboxyl-terminal tyrosine distinguishes the B*2706-bound peptide repertoire from those of B*2704 and other HLA-B27 subtypes associated to ankylosing spondylitis. Tissue Antigens 1997: 49: 215-21.
40. Tieng V, Dulphy N, Boisgérault F, Tamouza R, Charron D, Toubert A. HLA-B*2707 peptide motif: Tyr C-terminal anchor is not shared by all disease-associated subtypes. Immunogenetics 1997: 47: 103-5.
41. Fiorillo MT, Meadows L, D'Amato M et al. Susceptibility to ankylosing spondylitis correlates with the C-terminal residue of peptides presented by various HLA-B27 sub-types. Eur J Immunol 1997: 27: 368-73.
42. Alvarez I, Marti M, Vazquez J, Camafeita E, Ogueta S, Lopez de Castro JA. The Cys-67 residue of HLA-B27 influences cell surface stability, peptide specificity, and T-cell antigen presentation. J Biol Chem 2001: 276: 48740-7.
43. Krebs S, Rognan D, Lopez de Castro JA. Long-range effects in protein-ligand interactions mediate peptide specificity in the human major histocompatibilty antigen HLA-B27 (B*2701). Protein Sci 1999: 8: 1393-9.
44. Sesma L, Montserrat V, Lamas JR, Marina A, Vazquez J, Lopez de Castro JA. The peptide repertoires of HLA-B27 subtypes differentially associated to spondyloarthropathy (B*2704 and B*2706) differ by specific changes at three anchor positions. J Biol Chem 2002: 277: 16744-9.
45. Ramos M, Paradela A, Vazquez M, Marina A, Vazquez J. Lopez de Castro JA. Differential association of HLA-B*2705 and B*2709 to ankylosing spondylitis correlates with limited peptide subsets but not with altered cell surface stability. J Biol Chem 2002: 277: 28749-56.
46. Marti M, Alvarez I, Montserrat V, Lopez de Castro JA. Large sharing of T-cell epitopes and natural ligands between HLA-B27 subtypes (B*2702 and B*2705) associated with spondyloarthritis. Tissue Antigens 2001: 58: 35142.
47. Luz JG, Huang M, Garcia KC et al. Structural comparison of allogeneic and syngeneic T cell receptor-peptide-major histocompatibility complex complexes: A buried alloreactive mutation subtly alters peptide presentation substantially increasing V (beta) interactions. J Exp Med 2002: 195: 1175-86.
48. Uchanska-Ziegler BR, Hilling M, Hülsmayer W et al. Crystal structures of HLA-B*2705 and B*2709 complexed with the same peptide differ only marginally. In: Hansen JA, Dupont B, eds. HLA 2002. Immunobiology of the Human MHC. Seattle: IHWG Press, 2002, in press.
49. Lamas JR, Brooks JM, Galocha B, Rickinson AB, Lopez de Castro JA. Relationship between peptide binding and T cell epitope selection: A study with subtypes of HLA-B27. Int Immunol 1998: 10: 259-66.
50. Fiorillo MT, Greco G, Maragno M et al. The naturally occurring polymorphism Asp116 - >His116, differentiating the ankylosing spondylitis-associated HLA-B*2705 from the non- associated HLA-B*2709 subtype, influences peptide-specific CD8 T cell recognition. Eur J Immunol 1998: 28: 2508-16.
51. Paradela A, Garcia-Peydro M, Vazquez J, Rognan D, Lopez de Castro JA. The same natural ligand is involved in allorecognition of multiple HLA-B27 subtypes by a single T cell clone: Role of peptide and the MHC molecule in alloreactivity. J Immunol 1998: 161: 5481-90.
52. Lopez D, Garcia Hoyo R, Lopez de Castro JA. Clonal analysis of alloreactive T cell responses against the closely related B*2705 and B*2703 subtypes. Implications for HLA-B27 association to spondyloarthropathy. J Immunol 1994: 152: 5557-71.
53. Garcia-Peydro M, Marti M, Lopez de Castro JA. High T cell epitope sharing between two HLA-B27 subtypes (B*2705 and B*2709) differentially associated to ankylosing spondylitis. J Immunol 1999: 163: 2299-305.
54. Scofield RH, Kurien B, Gross T, Warren WL, Harley JB. HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: Implications for spondyloarthropathies. Lancet 1995: 345: 1542-4.
55. Garcia F, Marina A, Albar JP, Lopez de Castro JA. HLA-B27 presents a peptide from a polymorphic region of its own molecule with homology to proteins from arthritogenic bacteria. Tissue Antigens 1997: 49: 23-8.
56. Ramos M, Alvarez I, Sesma L, Logean A, Rogman D, Lopez de Castro JA. Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J Biol Chem 2002: 277: 87573-81.
57. Alvarez I, Sesma L, Marcilla M et al. Identification of novel HLA-B27 ligands derived from polymorphic regions of its own or other class I molecules based on direct generation by 20S proteasome. J Biol Chem 2001: 276: 32729-37.
58. Khare SD, Luthra HS, David CS. Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking β2-microglobulin: A model of human spondyloarthropathies. J Exp Med 1995: 182: 1153-8.
59. Khare SD, Hansen J, Luthra HS, David CS. HLA-B27 heavy chain contribute to spontaneous inflammatory disease in B27/human β2-microglobulin (β2m) double transgenic mice with disrupted mouse β2m. J Clin Invest 1996: 98: 2746-55.
60. Kingsbury DJ, Mear JP, Witte DP, Taurog JD, Roopenian DC, Colbert RA. Development of spontaneous arthritis in beta2 micro-globulin-deficient mice expression of HLA-B27: Association with deficiency of endogenous major histocompatibility complex class I expression. Arthritis Rheum 2000: 43: 2290-6.
61. Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE. Susceptibility to inflammatory disease in transgenic rat lines correlates with level of B27 expression. J Immunol 1993: 150: 4168-78.
62. Breban M, Fernandez-Sueiro JL, Richardson JA et al. T cells, but not thymic exposure to HLA-B27, are required: For the inflammatory disease of HLA-B27 transgenic rats. J Immunol 1996: 156: 794-803.
63. Rock KL, Gamble S, Rothstein L, Gramm C, Benacerraf B. Dissociation of beta 2-micro-globulin leads to the accumulation of a substantial pool of inactive class I MHC heavy chains on the cell surface. Cell 1991: 65: 611-20.
64. Allen RL, O'Callaghan CA, McMichael AJ, Bowness P. Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. J Immunol 1999: 162: 5045-8.
65. Bird LA, Peh CA, Kollnberger S et al. Identification and characterisation of cell surface HLA-B27 homodimers. Tissue Antigens 2002: 59: 36.
66. Dangoria NS, DeLay ML, Kingsbury DJ et al. HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum. J Biol Chem 2002: 277: 23459-68.
67. Boyle LH, Goodall JC, Opat SS, Gaston JS. The recognition of HLA-B27 by human CD4 (+) T lymphocytes. J Immunol 2001: 167: 2619-24.
68. Allen RL, Raine T, Haude A, Trowsdale J, Wilson MJ. Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. J Immunol 2001: 167: 5543-7.
69. Hughes EA, Hammond C, Cresswell P. Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. Proc Natl Acad Sci U S A 1997: 94: 1896-901.
70. Ikawa T, Ikeda M, Yamaguchi A et al. Expression of arthritis-causing HLA-B27 on Hela cells promotes induction of c-fos in response to in vitro invasion by Salmonella typhimurium. J Clin Invest 1998: 101: 263-72.
71. Neefjes JJ, Ploegh HL. Allele and locus-specific differences in cell surface expression and the association of HLA class I heavy chain with beta 2-microglobulin: Differential effects of inhibition of glycosylation on class I subunit association. Eur J Immunol 1988: 18: 801-10.
72. Hill A, Takiguchi M, McMichael A. Different rates of HLA class I molecule assembly which are determined by amino acid sequence in the alpha 2 domain. Immunogenetics 1993: 37: 95-101.
73. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. Viral subversion of the immune system. Annu Rev Immunol 2000: 18: 861-926.
74. Taurog JD, Richardson JA, Croft JT et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994: 180: 2359-64.
75. Kirveskari J, He Q, Leirisalo-Repo M et al. Enterobacterial infection modulates major histocompatibility complex class I expression on mononuclear cells. Immunology 1999: 97: 420-8.
76. Zhong G, Liu L, Fan T, Fan P, Ji H. Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells. J Exp Med 2000: 191: 1525-34.
77. Zhong G, Fan P, Ji H, Dong F, Huang Y. Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. J Exp Med 2001: 193: 935-42.
78. Neisig A, Wubbolts R, Zang X, Melief C, Neefjes J. Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing. J Immunol 1996: 156: 3196-206.
79. Turnquist HR, Thomas HJ, Prilliman KR, Lutz CT, Hildebrand WH, Solheim JC. HLA-B polymorphism affects interactions with multiple endoplasmic reticulum proteins. Eur J Immunol 2000: 30: 3021-8.
80. Turnquist HR, Schenk EL, McIlhaney MM, Hickman HD, Hildebrand WH, Solheim JC. Disparate binding of chaperone proteins by HLA-A subtypes. Immunogenetics 2002: 53: 830-4.
81. Hildebrand WH, Turnquist HR, Prilliman KR et al. HLA class I polymorphism has a dual impact on ligand binding and chaperone interaction. Hum Immunol 2002: 63: 248-55.